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ABSTRACT
Background: Memantine is licensed for moderate-to-
severe Alzheimer’s disease (AD). National Institute for
Clinical Excellence (NICE) guidance does not
recommend the use of memantine in combination with
cholinesterase inhibitors (acetylcholinesterase
inhibitor (AChEI)). The underpinning meta-analysis
was disputed by the manufacturer.
Objectives: To compare the efﬁcacy of AChEI
monotherapy with combination memantine and AChEI
therapy in patients with moderate-to-severe AD and to
examine the impact of including unpublished data on
the results.
Design: Systematic review and meta-analysis of
randomised controlled trials.
Data sources: The Cochrane Dementia Group trial
register, ALOIS, searched for the last time on 3 May
2011.
Data synthesis: Data from four domains (clinical
global, cognition, function, behaviour and mood) were
pooled. Sensitivity analyses examined the impact on
the NICE-commissioned meta-analysis of restricting
data to patients with moderate-to-severe AD and of
including an unpublished trial of an extended release
preparation of memantine.
Results: Pooled data from the trials, which were
included in the NICE-commissioned meta-analysis but
which were restricted to moderate-to-severe AD only,
showed a small effect of combination therapy on
cognition (standardised mean difference
(SMD)¼ 0.29, 95% CI  0.45 to  0.14). Adding data
from an unpublished trial of an extended release
memantine (total three trials, 1317 participants)
showed a small beneﬁt of combination therapy on
global scores (SMD¼ 0.20, 95% CI  0.31 to  0.09),
cognition (SMD¼ 0.25, 95% CI  0.36 to  0.14)
and behaviour and mood (SMD¼ 0.17, 95%
CI  0.32 to  0.03) but not on function (SMD¼ 0.04,
95% CI  0.21 to 0.13) at 6 months. No clinical data
have been reported from a 1-year trial, although this
found ‘no signiﬁcant beneﬁt’ on any clinical measures
at 1 year.
Conclusions: These results suggest that there may be
a small beneﬁt at 6 months of adding memantine to
AChEIs. However, the impact on clinical global
impression depends on exactly which studies are
included, and there is no beneﬁt on function, so its
clinical relevance is not robustly demonstrated.
Currently available information from randomised
controlled trails indicates no beneﬁt of combination
therapy over monotherapy at 1 year. Legislation on the
form and content of registry posted results is needed
in Europe.
INTRODUCTION
Two classes of drugs are licensed by the
European Medicines Agency for the treat-
ment of Alzheimer’s disease (AD): acetyl-
cholinesterase inhibitors (AChEIs) for mild-
to-moderate disease and memantine for
moderate (Mini-Mental State Examination
(MMSE) 10e19) and severe disease (MMSE
<10).
1 Memantine is a moderate afﬁnity non-
competitive NMDA receptor antagonist,
which blocks the effects of tonic pathologi-
cally elevated levels of glutamate that may
lead toneuronal dysfunction. It has a small
but consistent effect, but its place in therapy
has been controversial in Europe.
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ARTICLE SUMMARY
Article focus
- To compare the efﬁcacy of AChEI monotherapy
with combination memantine and AChEI therapy
in patients with moderate-to-severe AD.
- To examine the impact of including unpublished
data on the results.
Key messages
- Combination AChEI and memantine therapy is
of greater beneﬁt in AD than AChEIs alone,
but the clinical relevance depends on exactly
which studies are included so is not robustly
demonstrated.
- Unpublished data in registry postings can still
obscure important negative clinical ﬁndings.
- International harmonisation of reporting of all
clinical variables is needed.
Strengths and limitations of this study
- Systematic review including sources of
unpublished data.
- Not all relevant data were available for
meta-analysis.
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Open Access ResearchBoth National Institute for Clinical Excellence (NICE)
and IQWiG (the German Institute for Quality and Efﬁ-
ciency in Healthcare) have revised their original
conclusions that there was insufﬁcient evidence to
recommend memantine as a monotherapy for AD.
2e4
Following the release of IQWiQ’s original report in
2009,
3 the manufacturer of ‘Axura’ memantine, Merz,
submitted a responder analysis, presenting data from
two previously excluded unpublished trials, IE2101 and
MD-22. Despite initially stating that this analysis could
not be used,
5 IQWiG revised their conclusion and in
2011 reported that the new data provided proof of
a beneﬁt of memantine on cognition in AD.
4
The NICE currently recommends the use of meman-
tine in severe disease or as a second-line treatment in
moderate disease for patients who are intolerant or have
a contraindication to AChEIs. However, it does not
recommend the use of memantine in combination with
AChEIs, stating that there is ‘a lack of evidence of
additional clinical efﬁcacy compared with mono-
therapy’.
2 This contrasts with the conclusions of a recent
company-sponsored non-systematic review,
6 which
asserts that it is “safe, well-tolerated, and may represent
the current gold standard for treatment of moderate-
severe AD and possibly mild-to-moderate AD as well.”
Memantine does not have a licence for mild AD, and
evidence is lacking for a clinical beneﬁt in this group.
7
In the meta-analysis, which informed the guidance
(TA217),
8 two trials are included in the analysis of
combination therapy.
91 0Data for cognitive and activities
of daily living (ADL)/function outcomes were contro-
versially not pooled on the grounds that different
scoring systems were used by the included trials. Pooled
analyses in the other domains (global and behavioural)
showed no beneﬁt. A further source of dispute was that
data from patients with mild AD in one of the trials (MD-
12)
10 were included despite the separate availability of
data (in Winblad et al (2007)
11) for just the subgroup of
patients with moderate AD, which falls within the
licensed indication.
As part of a Cochrane review, we conducted a systematic
review, meta-analysis and sensitivity analyses to examine
the impact of these issues and of the inclusion of
unpublished data on the efﬁcacy of combination
memantine and AChEI therapy in moderate-to-severe AD.
METHODS
Search methods
ALOIS, the Cochrane Dementia and Cognitive Improve-
ment Group’s comprehensive, free access register of
trials
12 that contain records from all relevant sources, was
searched for the ﬁnal time on 3 May 2011. The search
terms used were memantine, D-145, DMAA, DRG-0267,
ebixa, abixa, axura, akatinol, memox and namenda.
ALOIS is maintained by the Trials Search co-ordinator
and contains studies in the areas of dementia prevention,
dementia treatment and cognitive enhancement in
healthy participants. The studies are identiﬁed from:
1. Monthly searches of a number of major healthcare
databases: MEDLINE, EMBASE, CINAHL, PsycINFO
and LILACS.
2. Monthly searches of a number of national and
international trial registers: ISRCTN; UMIN (Japan’s
Trial Registry); ICTRP/WHO portal (which covers
ClinicalTrials.gov; ISRCTN; the Chinese Clinical
Trials Register; the German Clinical Trials Register;
the Iranian Registry of Clinical Trials and the
Netherlands National Trials Register, plus others).
3. Quarterly search of The Cochrane Library’s Central
Register of Controlled Trials (CENTRAL).
4. Six-monthly searches of a number of grey literature
sources: ISI Web of Knowledge Conference Proceed-
ings; Index to Theses; Australasian Digital Theses.
Details of the search strategies used for the retrieval of
reports of trials from the healthcare databases, from
Cochrane CENTRAL and from conference proceedings
can be viewed in the ‘Methods used in reviews’ section
within the editorial information section of the Dementia
and Cognitive Improvement Group’s website.
13
Additionally, the clinical trials registries of Lundbeck,
Forest and the Japanese registry the Japanese Pharma-
ceutical Information Centre, the websites of the US Food
and Drug Administration, the European Medicines
Agency, NICE and press releases of manufacturers
(Lundbeck, Merz, Forest, Suntori, Asubio, Daiichi) and
all conference posters of studies sponsored by Merz,
Lundbeck and Forest presented in 2004e2009 were
studied in detail. Authors and companies were contacted
directly with requests for missing information. A full
account of the search strategy is available in the full
Cochrane review from which this paper is drawn.
Trial inclusion criteria
Trials were included if they were (1) double-blind,
parallel group, placebo-controlled randomised trials of
memantine in patients with moderate-to-severe AD who
were taking AChEIs, (2) sample selection criteria were
speciﬁed and diagnosis used established criteria and (3)
outcome instruments were speciﬁed.
Data extraction
We extracted clinical and demographic characteristics
and outcome data relating to patients with moderate and
severe AD from the trial reports and, where not available
from primary reports, from a company-sponsored meta-
analysis, which was conducted during the European
regulatory review process.
11 The data were extracted
independently by at least two people, and discrepancies
were resolved by discussion. The outcomes of interest
were clinical global impression, cognitive function, func-
tional performance in ADL and mood and behavioural
disturbance. These were assessed using instruments,
including the Clinician’s Interview-Based Impression of
Change plus caregiver’s input (CIBIC-plus), the
Alzheimer’s Disease Assessment ScaleeCognitive subscale
(ADAS-Cog) and Severe Impairment Battery (SIB), the
Alzheimer’s Disease Cooperative StudyeActivities of Daily
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Neuropsychiatric Inventory (NPI).
Data synthesis and analysis
Data from each of the four clinical domains were pooled
separately, and a random-effects model (DerSimonian-
Laird) was used to estimate differences between groups.
Effect sizes were presented as standardised mean differ-
ences (SMDs)dthe absolute mean difference divided by
the SDdwith 95% CIs and p values, calculated using
Revman V.5.0 software.
14 This meant that data could be
pooled when different rating scales (eg, SIB and ADAS-
Cog) were used to assess the same outcome. In the
TA217 assessment report, all effect sizes were presented
as weighted mean differences (WMDs), and data were
not pooled when included trials used different rating
scales. In this review, we have replicated the ﬁndings of
the TA217 report for comparison, presenting them ﬁrst
as WMDs (as in the original report) in analysis 1a, and
then as SMDs in analysis 1b.
Sensitivity analyses were performed to examine the
effect sizes in the NICE-commissioned assessment
report
8 in comparison with those derived from all avail-
able data, which are as follows:
1a. Replication of TA217 assessment report analysis,
presented as WMDs.
1b. Replication of TA217 assessment report analysis,
presented as SMDs for comparison.
2. Pooled data from trials included in the TA217
assessment report, presented as SMDs, excluding
data from patients with mild disease.
3. As in 2, but from all trials meeting our inclusion
criteria.
RESULTS
Description of studies
Five trials were identiﬁed (MD-02,
9 MD-12,
10 MD-50,
15
Lu10112
16 and DOMINO-AD
17) that met inclusion
criteria, of which three (MD-02,
9 MD-12
10 and MD-50
15)
were included in this meta-analysis. Of these, MD-02 and
MD-12 were included in the TA217 assessment report
analysis of memantine combination therapy.
91 0One
trial (MD-02
9) was of patients with moderate-to-severe
disease (MMSE range 5e14, average score 10.0) and
another trial (MD-12
10) was of mild-to-moderate disease
(MMSE range 10e22, average score 16.9). Data for the
subgroup of patients in MD-12 with moderate AD
were available through a published company-sponsored
meta-analysis.
11 MD-50
15 studied an extended release
(ER) preparation of 28 mg/day, which has recently been
granted a licence by the US Food and Drug Adminis-
tration
18 but is not currently marketed in the USA, is not
licensed in Europe and would have been ineligible for
inclusion in the NICE meta-analysis.
Two 12-month trials (Lu10112
16 and DOMINO-AD
17)
of combination therapy that met trial inclusion criteria
were excluded from this review. First, a randomised
controlled trial (Lu10112
16) of 277 patients with
moderate AD in which the primary was an imaging
outcome, and in which 72% of patients were taking an
AChEI, was completed in February 2009. A conference
poster in September 2009
19 and a registry posting in May
2010
16 did not report details of important clinical data
(ADAS-Cog, Neuropsychiatric Inventory, time to institu-
tionalisation) but reported that there was no signiﬁcant
beneﬁt of memantine on these measures at 12 months.
The cut-off point for inclusion in the TA217 meta-anal-
ysis was March 2010.
8 Total brain atrophy rates were
greater in those taking combination therapy than in
those taking memantine alone.
19 Second, data were not
yet available from the DOMINO-AD trial,
17 which
includes comparison of monotheraphy and combination
therapy and is due to report shortly.
Participants
The total number of participants was 1317. All patients
were diagnosed with AD, classed as mild, moderate or
severe disease based on their MMSE score. Table 1 shows
the baseline characteristics of participants.
Interventions
MD-02 and MD-12 compared the efﬁcacy and safety of
adding 20 mg/day memantine with placebo in patients
receiving stable treatment with donepezil (an AChEI).
MD-50 compared the efﬁcacy and safety of adding an ER
preparation of 28 mg/day memantine, equivalent to
20 mg daily, with placebo in patients receiving a stable
dose of any cholinesterase inhibitor.
Outcome measures
The primary outcomes of interest were clinical global
impression, cognitive function, functional performance
in ADL and behavioural and mood disturbance.
Quality of included studies
The commercially sponsored studies conducted after
1993 are likely to have conformed to International
Conference on Harmonisation Good Clinical Practice
Figure 1 Clinical global (CIBIC-
plus). ChEI, cholinesterase
inhibitor; ER, extended release;
LOCF, last observation carried
forward; OC, observed case;
SMD, standardised mean
difference.
Study or subgroup
MD-02/Tariot 2004* 9
MD-12/Porsteinsson/Mods† 10
MD-50/Grossberg 2008‡ 15
Total (95% CI)
Heterogeneity: τ²=0.00; χ²=2.19, df=2 (p=0.33); I²=9%
Test for overall effect: Z=3.47 (p=0.0005)
Mean
4.41
4.47
3.8
SD
1.04
0.98
1.2
Total
198
135
333
666
Mean
4.66
4.51
4.1
SD
1.05
0.98
1.2
Total
196
125
328
649
Weight
30.6%
20.9%
48.5%
100.0%
IV, Random, 95% CI
–0.24 (–0.44 to –0.04)
–0.04 (–0.28 to 0.20)
–0.25 (–0.40 to –0.10)
–0.20 (–0.32 to –0.09)
Memantine + ChEI ChEI monotherapy SMD
* LOCF; 20 mg daily
† From Winblad et al 200711; OC; 20 mg daily
‡ Unpublished registry data; LOCF; 28 mg ER preparation
SMD
IV, Random, 95% CI
–1 –0.5 0 0.5 1
Favours memantine + ChEI Favours ChEI monotherapy
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their sequence generation, allocation concealment and
methods of blinding. In the included studies, the char-
acteristics of the treatment and placebo groups were well
balanced at baseline (table 1). The risk of bias of the
included studies was judged to be low as indicated in the
‘risk of bias’ tables in the main Cochrane Review from
which this systematic review is derived.
Results of individual studies
Of the three included studies, MD-02
9 showed a signiﬁ-
cant beneﬁt of combination therapy (memantine plus
AChEI) compared with AChEI monotherapy on cogni-
tion, ADL, global outcome and behaviour. Combination
therapy was well tolerated. MD-12
10 showed no advan-
tage of combination therapy compared with AChEI
monotherapy in any domain in the overall group of
patients with mild as well as moderate disease. There
were no signiﬁcant differences in safety or tolerability
between the two groups. Data from the subset of patients
in MD-12
10 with moderate disease were taken from the
meta-analysis by Winblad et al (2007).
11 MD-50
15 showed
a statistically signiﬁcant improvement from combination
memantine ER plus AChEI therapy compared with
AChEI monotherapy ER on cognition, global improve-
ment and behaviour, but not on function, after
6 months. Memantine ER was well tolerated.
Results of synthesis of studies
The synthesis of data from trials of memantine combi-
nation therapy is summarised in table 2 and ﬁgures 1e4.
Analysis 1a shows the analysis conducted in TA127.
Analysis 1b shows that had TA127 pooled cognitive and
functional data across different instruments using
standardisation; there would still have been no domains
where combination therapy was signiﬁcantly better than
AChEI monotherapy. Analysis 2 shows the impact of
excluding data from patients with mild disease: there was
a small (SMD¼ 0.29, 95% CI  0.45 to  0.14) signiﬁ-
cant beneﬁt of memantine combination therapy on
cognition but not on any other outcome. Analysis 3, the
most inclusive analysis, shows that when data from the
memantine ER trial (MD-50
15) was also pooled, the small
beneﬁt on cognition persisted (SMD¼ 0.25, 95% CI
 0.36 to  0.14), and there were also small signiﬁcant
beneﬁts of combination therapy on the global improve-
ment score (SMD¼ 0.20, 95% CI  0.32 to  0.09) and
on behaviour and mood (SMD¼ 0.17, 95% CI  0.32 to
 0.03) but not on function (SMD¼ 0.04, 95% CI  0.21
to 0.13).
DISCUSSION
This systematic review and meta-analysis suggests a small
but signiﬁcant beneﬁt of memantine combination
therapy on cognitive, global and behaviour measures,
but not on function/ADL, when data from all included
trials, including one trial of ER memantine, were pooled.
When data from the trials included in the TA217 meta-
analysis, but from patients with moderate-to-severe
disease only, were pooled, there was a small, signiﬁcant
beneﬁt of combination therapy on cognition
(SMD¼0.29). This effect size is comparable to that seen
for memantine monotherapy. However, since the impact
on clinical global impression depends on exactly which
studies are included, and there is no beneﬁt on function,
the clinical relevance of combination therapy is not
robustly demonstrated.
Clinical data from a negative 1-year trial, which would
have been available at the time of the NICE meta-anal-
ysis, remain unpublished. The DOMINO study
17 is due
to report shortly. Whether pooling of these 1-year studies
would show a robust effect on clinical global remains to
be seen.
Data for patients with moderate AD from one trial
10
were only available as observed case data,
11 and it was
necessary to pool these with the last observation carried
Figure 2 Cognition (ADAS-Cog
and SIB). ChEI, cholinesterase
inhibitor; ER, extended release;
LOCF, last observation carried
forward; OC, observed case;
SMD, standardised mean
difference.
Study or subgroup
MD-02/Tariot 2004
* 9
MD-12/Porsteinsson/Mods
† 10
MD-50/Grossberg 2008
‡ 15
Total (95% CI)
Heterogeneity: τ²=0.00; χ²=1.50, df=2 (p=0.47); I²=0%
Test for overall effect: Z=4.54 (p<0.00001)
Mean
–0.9
0.85
–2.7
SD
9.43
5.95
11.1
Total
198
133
332
663
Mean
2.5
1.99
-0.3
SD
9.66
5.77
11.4
Total
196
123
327
646
Weight
29.9%
19.6%
50.5%
100.0%
IV, Random, 95% CI
–0.36 (–0.55 to –0.16)
–0.19 (–0.44 to 0.05)
–0.21 (-0.37 to –0.06)
–0.25 (–0.36 to –0.14)
Memantine + ChEI ChEI monotherapy SMD
* SIB; LOCF; 20 mg daily
† From Winblad et al 200711; ADAS-Cog; OC; 20 mg daily
‡ Unpublished registry data; SIB; LOCF; 28 mg ER preparation
SMD
IV, Random, 95% CI
–1 –0.5 0 0.5 1
Favours memantine + ChEI Favours ChEI monotherapy
Figure 3 Function (ACDS-
ADL19 and ADCS-ADL23). ChEI,
cholinesterase inhibitor; ER,
extended release; LOCF, last
observation carried forward; OC,
observed case; SMD,
standardised mean difference.
Study or subgroup
MD-02/Tariot 2004
* 9
MD-12/Porsteinsson/Mods
† 10
MD-50/Grossberg 2008
‡ 15
Total (95% CI)
Heterogeneity: τ²=0.01; χ²=4.79, df=2 (p=0.09); I²=58%
Test for overall effect: Z=0.46 (p=0.65)
Mean
2
3.63
–0.7
SD
7.04
7.01
6.9
Total
198
136
331
665
Mean
3.4
3.86
–1.3
SD
7.16
7.99
7.7
Total
197
125
328
650
Weight
33.0%
27.1%
39.9%
100.0%
IV, Random, 95% CI
–0.20 (–0.39 to 0.00)
–0.03 (–0.27 to 0.21)
0.08 (–0.07 to 0.23)
–0.04 (–0.21 to 0.13)
Memantine + ChEI ChEI monotherapy SMD
* LOCF; ADCS-ADL   ; 20 mg daily
 19
† From Winblad et al 200711; OC; ADCS-ADL   ; 20 mg daily
23
‡ Unpublished registry data; ADCS-ADL
19; LOCF; 28 mg ER preparation
SMD
IV, Random, 95% CI
–0.5 –0.25 0 0.25 0.5
Favours memantine + ChEI Favours ChEI monotherapy
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91 5which is not
methodologically ideal. In the full Cochrane review, this
strategy was shown to have no material effect on results.
The last observation carried forward treatment of
missing data is a conservative approach because dropout
rates are equivalent or slightly favour memantine.
Consideration of the cost-effectiveness of combination
AChEI and memantine was outside the scope of this
review.
To the extent that we found a signiﬁcant beneﬁt of
combination therapy on cognition, our analyses of the
available data contrast with the ﬁndings of the TA217
report,
8 which found no evidence of additional beneﬁt
of combination therapy. The explanations given by the
Peninsula Technology Assessment Group (PenTAG) for
not pooling data from the same clinical domain (“it is
not valid to synthesise these data on their original
scales”
8) or for not restricting analyses to data from the
licensed patient subgroup (“The upper range of the
MMSE scores for the participants of this study was
20.37.. this was only minimally over the threshold
of 20 (so we) include(d) this study.”)
20 remain
controversial.
The inclusion of unpublished registry data on the ER
preparation extends the evidence of beneﬁt of combi-
nation therapy at 6 months. The dose of 28 mg
memantine in this preparation was designed to be
equivalent to 20 mg daily of the currently marketed
preparation.
21 However, the trend for an adverse effect
on ADL may account for the fact that these data have not
been published in peer review literature. Although there
is biological plausibility to the possibility of dose-related
adverse effects of memantine
22 and memantine is asso-
ciated with more rapid neurological decline in cogni-
tively impaired patients with multiple sclerosis,
23 24
memantine is well tolerated over 6 months, with slightly
fewer dropouts in the memantine than placebo arms,
and long-term open-label follow-up studies do not
suggest an obvious safety signal.
25e27 There are no long-
term, randomised placebo-controlled studies to address
this issue directly.
Nevertheless, we ﬁnd the beneﬁt of combination
therapy to be less convincing than other reviewers,
6
primarily because important data are missing from
registry posting of trial results. Posting of clinical data is
not mandatory for trials sponsored by companies who are
not the Marketing Authorisation Holder in the USA.
However, the fact that clinical data have not been released
from the 12-month trial, Lu10112,
16 is disturbing for two
reasons. First, cerebral atrophy rates were greater in those
taking combination therapy than in those taking
memantine alone.
19 While the presented analysis suggests
that this unexpected ﬁnding of increased atrophy was
attributable to the AChEI rather than the memantine,
there is no information about whether this is reﬂected in
the clinical domains. Second, the reason given for not
posting the clinical data is revealing: sponsors who are not
marketing authorisation holders in the USA are not
obligated by US public law 110-85. This law mandates the
posting of deﬁned clinical data items on registries within
a year of study completion.
The greatest beneﬁt of registries is ensuring the
timeliness of the release of results. Without this, there
are obvious incentives to delay the release of negative
data until as close to the end of patent life as possible.
However, registries are likely to become the preferred
repository of incomplete or negative data. This makes it
particularly important that harmonising legislation
speciﬁes in detail which clinical data must be posted.
Furthermore, until there is harmonisation onto a single
registry, such as clinicaltrials.gov, systematic reviews
should routinely include comprehensive searches across
all registries.
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